| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1068965170 |
| P356 | DOI | 10.2119/MOLMED.2008.00123 |
| P932 | PMC publication ID | 2646824 |
| P698 | PubMed publication ID | 19148300 |
| P5875 | ResearchGate publication ID | 23792190 |
| P50 | author | H P Kalofonos | Q56432806 |
| Andreas A Argyriou | Q90289999 | ||
| P2860 | cites work | Cloning and characterization of HIV-1-inducible astrocyte elevated gene-1, AEG-1 | Q24304205 |
| Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma | Q24670606 | ||
| Astrocyte elevated gene-1: recent insights into a novel gene involved in tumor progression, metastasis and neurodegeneration | Q24676501 | ||
| Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. | Q27824850 | ||
| Temozolomide in newly diagnosed malignant gliomas: administered concomitantly with radiotherapy, and thereafter as consolidation treatment. | Q46544778 | ||
| Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study | Q46585156 | ||
| The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts | Q46652649 | ||
| Bevacizumab plus irinotecan in recurrent glioblastoma multiforme | Q46942082 | ||
| Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malig | Q48133104 | ||
| Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma | Q48264845 | ||
| Synergistic antiglioma activity of radiotherapy and enzastaurin | Q48315412 | ||
| Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. | Q48445523 | ||
| Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177. | Q48576018 | ||
| Prognostic impact of molecular markers in a series of 220 primary glioblastomas | Q48602532 | ||
| Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study. | Q48868175 | ||
| Angiogenic factors in the cerebrospinal fluid of patients with astrocytic brain tumors. | Q51990859 | ||
| Use of monoclonal anti-EGFR antibody in the radioimmunotherapy of malignant gliomas in the context of EGFR expression in grade III and IV tumors. | Q55470032 | ||
| Oligodendroglial tumors frequently demonstrate hypermethylation of the CDKN2A (MTS1, p16INK4a), p14ARF, and CDKN2B (MTS2, p15INK4b) tumor suppressor genes. | Q55473852 | ||
| Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. | Q55479721 | ||
| Targeted imaging of human endothelial-specific marker in a model of adoptive cell transfer | Q57187516 | ||
| Anti-epidermal growth factor receptor monoclonal antibody cetuximab augments radiation effects in glioblastoma multiforme in vitro and in vivo | Q81194639 | ||
| PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization | Q95779435 | ||
| Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma | Q27860910 | ||
| Histone deacetylase inhibitors in cancer treatment | Q28210204 | ||
| Upstream and downstream of mTOR | Q28277365 | ||
| Brain magnetic resonance imaging with contrast dependent on blood oxygenation | Q29618145 | ||
| AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. | Q30490422 | ||
| Modulation of radiation response by histone deacetylase inhibition | Q33214371 | ||
| Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma | Q33286242 | ||
| Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme | Q33369628 | ||
| Clinical translation of angiogenesis inhibitors | Q34152769 | ||
| Blocking oncogenic Ras signaling for cancer therapy | Q34311585 | ||
| Targeting protein kinase C: new therapeutic opportunities against high-grade malignant gliomas? | Q34537883 | ||
| Anaplastic astrocytoma in adults. | Q34579207 | ||
| Genes and pathways driving glioblastomas in humans and murine disease models | Q35143797 | ||
| Radioimmunotherapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas | Q35669137 | ||
| Recombinant toxins as novel therapeutic agents | Q35671038 | ||
| Genetic pathways to primary and secondary glioblastoma | Q35757144 | ||
| Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma | Q35800541 | ||
| Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects | Q35951631 | ||
| Genetic pathways to glioblastomas | Q36094814 | ||
| Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose | Q36320675 | ||
| Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents | Q36395924 | ||
| Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours | Q36400537 | ||
| Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). | Q36610166 | ||
| Mechanisms of chemoresistance to alkylating agents in malignant glioma | Q36726010 | ||
| Lessons learned in the development of targeted therapy for malignant gliomas. | Q36874488 | ||
| Integrins: molecular determinants of glioma invasion | Q36978429 | ||
| Angiogenesis and gliomas: current issues and development of surrogate markers | Q37094967 | ||
| Treatment options for malignant gliomas, emphasizing towards new molecularly targeted therapies | Q37207729 | ||
| Exogenous platelet-derived growth factor (PDGF) induces human astrocytoma cell line proliferation. | Q40094951 | ||
| Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. | Q40469450 | ||
| Noninvasive MR imaging of magnetically labeled stem cells to directly identify neovasculature in a glioma model | Q40522104 | ||
| Dynamic, contrast-enhanced perfusion MRI in mouse gliomas: correlation with histopathology | Q40592930 | ||
| Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist | Q43517798 | ||
| Diagnostic potential of short echo time MR spectroscopy of gliomas with single-voxel and point-resolved spatially localised proton spectroscopy of brain | Q43632743 | ||
| Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib | Q43742602 | ||
| Phase II trial of gefitinib in recurrent glioblastoma | Q44669178 | ||
| Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. | Q46129562 | ||
| Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. | Q46410598 | ||
| P433 | issue | 3-4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 115-122 | |
| P577 | publication date | 2009-03-01 | |
| P1433 | published in | Molecular Medicine | Q6895961 |
| P1476 | title | Molecularly targeted therapies for malignant gliomas | |
| P478 | volume | 15 |
| Q42358218 | Amlexanox, a selective inhibitor of IKBKE, generates anti-tumoral effects by disrupting the Hippo pathway in human glioblastoma cell lines |
| Q90415267 | Effect of VEGFR, PDGFR and PI3K/mTOR Targeting in Glioblastoma |
| Q39140400 | Endothelial differentiation of adipose tissue-derived mesenchymal stromal cells in glioma tumors: implications for cell-based therapy. |
| Q34127138 | Experimental approaches for the treatment of malignant gliomas |
| Q35845255 | Expression of podoplanin in human astrocytic brain tumors is controlled by the PI3K-AKT-AP-1 signaling pathway and promoter methylation |
| Q36534930 | Frontiers in Suicide Gene Therapy of Cancer |
| Q34243638 | Glioblastoma therapy with cytotoxic mesenchymal stromal cells optimized by bioluminescence imaging of tumor and therapeutic cell response |
| Q38633650 | Long non-coding RNA Fer-1-like family member 4 is overexpressed in human glioblastoma and regulates the tumorigenicity of glioma cells |
| Q60921219 | Long noncoding RNA OIP5-AS1 targets Wnt-7b to affect glioma progression via modulation of miR-410 |
| Q38439094 | Long noncoding RNA profiles reveal three molecular subtypes in glioma |
| Q33591900 | Metabotropic glutamate receptors as a new therapeutic target for malignant gliomas |
| Q34043232 | Multivariate signaling regulation by SHP2 differentially controls proliferation and therapeutic response in glioma cells |
| Q33801496 | Proteomic studies coupled with RNAi methodologies can shed further light on the downstream effects of telomerase in glioma |
| Q37637707 | Signaling in malignant astrocytomas: role of neural stem cells and its therapeutic implications. |
| Q36603152 | Type-3 metabotropic glutamate receptors regulate chemoresistance in glioma stem cells, and their levels are inversely related to survival in patients with malignant gliomas |
Search more.